NASDAQ
ATRC
Last Price
US $34.32
KEY FIGURES
MKT CAP
$1.7B
EPS
TTM
$-0.10
PEG
TTM
-
P/E
TTM
N/M
P/S
TTM
3.00x
YIELD
0.00%
GROWTH
Revenue Y/Y
Valuation
Financial
Performance
Financial stability - Cash flow debt coverage.
AtriCure, Inc. cash flow to debt ratio of 65.14% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.
Financial stability - Healthy cash flow growth.
AtriCure, Inc.'s free cash flow has increased -529.00% from $-11.26M last year to $48.28M, signaling increasing performance
Financial stability - Healthy debt to equity ratio.
AtriCure, Inc.'s debt to equity ratio is 0.15, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial stability - Healthy debt to equity ratio development.
AtriCure, Inc.'s debt has decreased relative to shareholder equity from 0.17 last year to 0.15 today, signaling strengthened financials
Financial stability - Net debt/EBITDA.
AtriCure, Inc. has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability
Financial risk - ICR.
AtriCure, Inc.'s interest coverage ratio is -0.27, which means that the company struggles to meet interest obligations, signaling financial risk.
Financial stability - Profit margin growth.
AtriCure, Inc.'s profit margin has increased (-91.34%) in the last year from -9.61% to -0.83%, signaling increasing performance
Financial stability - Short term assets vs short term liabilities.
AtriCure, Inc.'s short-term assets of $322.52M exceed its short-term liabilities of $81.52M
Decreasing performance - ROA.
AtriCure, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
AtriCure, Inc.'s return on equity of -0.95%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
AtriCure, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
AtriCure, Inc. had positive net income in only 1.00 out of 5 years, indicating unstable earnings
Increasing performance - Free cash flow.
AtriCure, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures
Increasing performance - FCF yield.
AtriCure, Inc. has a free cash flow yield of 2.78%, which is above the 2.00% threshold, indicating strong cash generation relative to market value
Increasing performance - Healthy earnings growth.
AtriCure, Inc.'s yearly earnings has increased -74.39% since last year from $-44.70M to $-11.45M, signaling increasing performance
Increasing performance - Healthy revenue growth.
AtriCure, Inc.'s yearly revenue has increased 14.88% since last year from $465.31M to $534.53M, signaling increasing performance
Decreasing performance - ROIC.
ROIC -0.34% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Increasing performance - 3-year revenue CAGR.
AtriCure, Inc.'s 3-year revenue CAGR of 17.40% is positive, indicating growing revenue over the past 3 years
Increasing performance - Revenue consistency.
AtriCure, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
AtriCure, Inc. had positive ROE in only 1.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
AtriCure, Inc. has insufficient data to evaluate this check.
Overvalued - Earnings yield.
AtriCure, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
AtriCure, Inc. is overvalued relative to its fair value price of 3.82 based on EBITDA multiple model
Overvalued - EV/EBITDA.
AtriCure, Inc. has an EV/EBITDA ratio of 102.09x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings
Overvalued - PEG ratio value.
AtriCure, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Undervalued - P/B ratio.
AtriCure, Inc. has a price-to-book ratio of 3.37x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Undervalued - P/S ratio.
AtriCure, Inc. has a price-to-sales ratio of 3.00x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
-0.95%
Return on equity
ROIC: -0.34%
Valuation History
-350.5X
Price to Earnings
EV/EBITDA: 67.4X
Cash flow
Profit margin
20.95%
(FY vs FY)
EBITDA Y/Y
-
(FY vs FY)
Cash flow Y/Y
-
(FY vs FY)
Cash Flow (DCF)
Fair Value
Market $34.32
—
Default assumptions
EBITDA Multiple
Fair Value
Market $34.32
-88.87%
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.